Fatores prognósticos para pacientes com SARS-Cov
DOI:
https://doi.org/10.53660/CONJ-2069-2S51APalavras-chave:
SARS-Cov-2, COVID-19, D-dímero, Ivermectina, DiarréiaResumo
Vários medicamentos antiparasitários foram utilizados no tratamento de pacientes diagnosticados com COVID-19, mesmo sem a comprovação de sua eficácia por meio de estudos clínicos robustos. Apesar de todos os avanços atingidos desde o primeiro caso em 2020, ainda se faz necessário compreender o papel prognóstico das características clínicas dos pacientes, assim como o efeito dos tratamentos instituídos no início da pandemia sobre o desfecho da internação. Trata-se de um estudo quantitativo, transversal, observacional e correlacional que foi realizado no período de março a agosto de 2020, período identificado como primeira onda da COVID-19, em um hospital terciário, público, em Fortaleza, Ceará, no nordeste do Brasil. Foram incluídos pacientes que necessitaram de internação e avaliadas variáveis socidemográficas, clínicas e de tratamento. Este estudo evidenciou que o sintoma diarréia está associado ao desfecho do óbito, enquanto a anosmia está associada com maior chance de sobrevivência. O D-dímero acima do valor de normalidade aumentou em quatro vezes o risco de morte e foi identificado como um preditor do óbito. Dentre os medicamentos analisados, a ivermectina apresentou efeito protetor, reduzindo o risco de morte em 0,254 vezes, por outro lado, a nitazoxanida foi associada ao óbito. Assim, este estudo identificou um perfil prognóstico plausível, reforçando a necessidade premente de dados brasileiros para apropriação do cuidado sempre na direção conjunta de realocação dos subsídios dentro de um cenário público de saúde.
Downloads
Referências
BADAWI, A; RYOO, S. G; et al. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis., v. 49, p. 129–133, 2016.
BASTARD, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, v. 370, n. 6515, p. eabd4585, 2020.
BLUM, V. F et al. Nitazoxanide superiority to placebo to treat moderate COVID-19 A Pilot prove of concept randomized double-blind clinical trial. E Clinical Medicine, v. 37, p. 100981, 2021.
BRYANT, A; LAWRIE, T. A; DOWSWELL, T; et al. Ivermectin for prevention and treatment ofCOVID-19 infection: a systematic review,meta-analysis, and trial sequential analysis toinform clinical guidelines. Am J Ther., v. 28, n. 4, p. e434-e460, 2021.
BURKE, James M. et al. SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block. Rna, v. 27, n. 11, p. 1318-1329, 2021.
CALY L; DRUCE, J.D; CATTON, M. G; et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., v. 178, p. 104787, 2020.
CHANNAPPANAVAR, R; FETT, C; MACK, M: et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol, v. 98, p. 4046–4053, 2017.
CHEN, J; LIU, D; LIU, L; et al .A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (MedSci), v. 49, n. 2, 2020a.
CHEN, X; HU, W; LING, J; et al.Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients. medRxiv, v. 1, 2020b.
CONTI, P.; YOUNES, A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents, v. 34, n. 2, p. 339-343, 2020.
COUTARD, B. et al. A glicoproteína spike do novo coronavírus 2019-nCoV contém um local de clivagem semelhante à furina ausente no CoV do mesmo clado. Pesquisa antiviral , v. 176, p. 104742, 2020.
CUI, Pendurar; KONG, Yahui; ZHANG, Hong. Estresse oxidativo, disfunção mitocondrial e envelhecimento. Journal of Signal Transduction, v. 2012, 2012.
CUMMINGS, M. J; BALDWIN, M. R; ABRAMS, M. R; et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet., v. 395, n. 10239, p. 1763–70, 2020.
DANDEKAR, A. A; PERLMAN, S. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol, v. 5, p. 917–927, 2005.
FOSTER, K. J; JAUREGUI, E; TAJUDEEN, B; et al. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019 Letter / Ann Allergy Asthma Immunol., v. 125, p. 475-494, 2020.
GAREGNANI, L. I; MADRID, E; MEZA, N; et al. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med., v. 23, 2021.
GRASSELLI, G; ZANGRULLO, A.; ZANELLA, A; et al. For the COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, v. 1, 2020.
GUAN, W-J; NI, Z-Y; HU, Y; et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med, p. 1–13, 2020.
HELMS, J. High risk of thrombosis in patients with severe SARS CoV 2 infection: a multicenter prospective cohort study. Intensive Care Med, v. 46, p. 1089–1098, 2020.
HOPKINS, C.; VAIRA, L. A.; DE RIU, G.. Self‐reported olfactory loss in COVID‐19: is it really a favorable prognostic factor?. In: International forum of allergy & rhinology. Wiley-Blackwell, 2020.
HUANG, C; WANG, Y; LI ,X; et al. Clinical features of patients infected with 2019 Novel Coronavirus in Wuhan, China. Lancet, v. 395, p. 497–506, 2020.
HUNTER, J. D. Pneumonia associada à ventilação mecânica. Bmj , v. 344, 2012.
JOFFILY, L; UNGIEROWICZ, A; DAVIS, A. G; et al. The close relationship between sudden loss of smell and COVID-19. Braz J Otorhinolaryngol., v. 86, p. 632-638, 2020.
KIRKWOOD, T. B. L; AUSTAD, S. N; et al. Review article. Why do we age? Nature, p. 408, p. 233-238, 2000.
KONNO, Y. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep, v. 32, p. 108185, 2020.
KRAVVARITI, E. The effect of hydroxycholoquin on thrombosis prevention and antiphospholipid antibody leves and primary antiphospholipid syndrome: A Pilot open label randomized prospective study. Autoimmunity Reviews, v. 19, n. 4, 2020.
KUMAR, S. et al. Impacto econômico social do surto de COVID-19 na Índia. International Journal of Pervasive Computing and Communications , 2020.
LECHIEN, J. R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-rhino-laryngology, v. 277, n. 8, p. 2251-2261, 2020.
LIM , L. C. R; HOR, C. P; TAI , K. H; et al. Efficacy of Ivermectin Treatment on Disease ProgressionAmong Adults With Mild to Moderate COVID-19 and ComorbiditiesThe I-TECH Randomized Clinical Trial. JAMA Intern Med., v. 1, 2022.
LOPEZ-MEDINA, E. L; PEZ, P; HURTADO, I.C; et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19:a randomized clinical trial. JAMA, v. 325, n. 14, p. 1426-1435, 2021
MA, R. C. W; HOLT, R.I. G. COVID-19 and diabetes. Diabetic medicine : a journal of the British Diabetic Association, v. 32242990, 2020.
MAGALHÃES, J. J. F; MENDES, R. P. G; SILVA, C. T. A. Epidemiological and clinical characteristics of the first 557 successive patients with COVID-19 in Pernambuco state, Northeast Brazil. Travel Medicine and Infectious Disease, v. 38101884, p. 2-8, 2020.
MANOLIS, A. S. et al. COVID-19 infection: viral macro-and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. Journal of cardiovascular pharmacology and therapeutics, v. 26, n. 1, p. 12-24, 2021.
MANSOUR, S. M . Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. International Immunopharmacology, v. 99, 2021.
MAO, L; WANG, M; CHEN, S; et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. JAMA Neurol, v. 77, p. 683-690, 2020.
MENDONÇA, A; MENDES NETO, C. A;SUZUKI, F.A: et al. Olfactory dysfunction in COVID-19: a marker of good prognosis? Braz J Otorhinolaryngol., v. 20, 2020.
MISRA, D.P; GASPARIAN, A. Y; ZIMBA, 0; et al. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: Searching for repurposable drug candidates. Rheumatol. Int., v. 40, p. 1741–1751, 2020.
PAN, Shan L.; ZHANG, Sixuan. Do combate à pandemia de COVID-19 ao enfrentamento das metas de desenvolvimento sustentável: uma oportunidade para pesquisa responsável em sistemas de informação. International Journal of Information Management , v. 55, p. 102196, 2020.
PANUGANTI, B. A. et al. <? covid19?> Predicting COVID-19 Incidence Using Anosmia and Other COVID-19 Symptomatology: Preliminary Analysis Using Google and Twitter. Otolaryngology–Head and Neck Surgery, v. 163, n. 3, p. 491-497, 2020.
POPP, M; STEGEMMAN, M; METZENDORF, M; et al .Ivermectin for preventing and treating COVID-19.Cochrane Database Syst Rev., v. 7, n. 7, p. 015017, 2021.
PÓVOA, Ângela Cristiane Santos; NAKAMURA, Wilson Toshiro. Relevância da estrutura de dívida para os determinantes da estrutura de capital: um estudo com dados em painel. Revista Contemporânea de Contabilidade , v. 12, n. 25, pág. 3-25, 2015.
QUEROL-RIBELLES, R. M; TENIAS, J. M; QUEROL-BORRAS, J.M; et al. Plasma d dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest., v. 126, p. 1087–1092, 2004.
ROCCO, P. R. M, Early use of nitazoxanide in mild COVID-19 disease: randomised,placebo-controlled trial. The european respiratory journal, v. 58, n. 1, 2021.
ROSSIGNOL, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res., v. 110, p. 94–103, 2014.
SCHREZENMEIER, E., DÖRNER, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology, v. 16, n. 3, p. 155-166, 2020.
SHAW, A. T. et al. Morte seletiva de células cancerígenas mutantes K-ras por indutores de moléculas pequenas de estresse oxidativo. Proceedings of the National Academy of Sciences , v. 108, n. 21, pág. 8773-8778, 2011.
SINGH, J. et al. SARS-CoV-2 variants of concern are emerging in India. Nature medicine, v. 27, n. 7, p. 1131-1133, 2021.
SOUZA, W.M; BUSH, L; CANDIDO, E; et al.Epidemiological and clinical characteristics of
the COVID-19 epidemic in Brazil, Nature Human Behavior, v. 372, 2020.
SPETH, M. M. et al. <? covid19?> Olfactory dysfunction and sinonasal symptomatology in COVID-19: prevalence, severity, timing, and associated characteristics. Otolaryngology–Head and Neck Surgery, v. 163, n. 1, p. 114-120, 2020.
STAWICKI, S. P. et al. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. Journal of global infectious diseases, v. 12, n. 2, p. 47, 2020.
TANG, B. et al. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infectious disease modelling, v. 5, p. 248-255, 2020.
WANG, D; HU, B; HU, C; et al. Clinical characteristics of 138 hospitalized patientswith
Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA – J Am Med Assoc,
p. 1–9, 2020.
WHO, WORLD HEALTH ORGANIZATION. Naming the Coronavirus Disease (COVID-19
and the Virus That Causes it. 2020.
XIE, C. et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. International Journal of Infectious Diseases, v. 93, p. 264-267, 2020.
YAN,C.H; FARAJI, F; PRAJAPATHI, D.P; et al. Self-reported olfactory loss associates with
outpatient clinical course in COVID-19. Int Forum Allergy Rhinol., v. 10, p. 821-831, 2020.
YAO, H. et al. Arquitetura molecular do vírus SARS-CoV-2. Cell , v. 183, n. 3, pág. 730-738. e13, 2020.
ZHANG, S. et al. Contenção da COVID-19: a China fornece lições importantes para a resposta global. Fronteiras da Medicina , v. 14, n. 2, pág. 215-219, 2020.
ZHU, X. et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus research, v. 285, p. 198005, 2020.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Conjecturas
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
